Key result
Compared with imatinib, nilotinib increased acute coronary syndrome risk and dasatinib increased heart failure risk in CML patients.
Why the study?
Patients with CML treated with TKIs are at risk for cardiotoxicity, but risk estimates from clinical trials may be limited by healthier populations and short follow-up durations.
Does treatment with different tyrosine kinase inhibitors alter the risk of long-term cardiovascular adverse events and echocardiographic changes compared with imatinib in patients with chronic myelogenous leukemia?
Cohort (n=357)
No
Does treatment with different tyrosine kinase inhibitors alter the risk of long-term cardiovascular adverse events and echocardiographic changes compared with imatinib in patients with chronic myelogenous leukemia?
Answers are grounded in this paper and cite their sources.
In CML patients over a median 7.2-year follow-up, specific TKIs carry distinct long-term cardiovascular and echocardiographic risks compared to imatinib, such as increased ACS with nilotinib, heart failure with dasatinib, and LVEF reduction with ponatinib.
BACKGROUND: patients with chronic myelogenous leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) are at risk for cardiotoxicity. Risk estimates from clinical trials may be limited by healthier populations and short follow-up durations. MATERIALS AND METHODS: we evaluated the incidence of cardiovascular adverse events (CVD-AE) and echocardiographic changes as a secondary outcome in CML patients on TKIs, accounting for cardiovascular risk from prior TKI exposure. CML patients treated with TKIs at Cleveland Clinic (2007-2022) were included. TKIs analyzed were imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. Data included demographics, comorbidities, treatments, and follow-up. Outcomes were overall survival and major adverse cardiovascular events (MACE): acute coronary syndrome (ACS), heart failure, stroke, peripheral arterial disease, and revascularization. Pleural effusions, pericardial effusions and pulmonary hypertension were assessed. Echocardiograms were collected at baseline. Multivariable Cox regression and generalized linear mixed models were applied. RESULTS: among 357 patients (median age 56; 57% male; 85% White), 518 CVD-AE occurred during median follow-up of 7.2 years. Compared with imatinib, nilotinib was associated with increased ACS (HR 3.5, P = 0.02), dasatinib with heart failure (HR 2.5, P = 0.04), and dasatinib, and asciminib with pleural (HRs 3.5, 5.8; P < 0.05) and pericardial effusions (HR 5.1, 21.6; P < 0.05). Dasatinib was associated with lower venous thrombosis (HR 0.1, P = 0.02). MACE incidence did not differ significantly among TKIs. Among 69 patients with serial echocardiograms, ponatinib decreased left ventricular ejection fraction (β = -5.2, P = 0.008) and bosutinib increased global longitudinal strain (β = 3.0, P = 0.037). CONCLUSION: Cardiovascular risks differ among TKIs, and therapy duration influences echocardiographic changes.
No takes yet. Share an insight, caveat, or question.
Zureigat et al. (2026) conducted a cohort in Chronic myelogenous leukemia (n=357). Tyrosine kinase inhibitors (dasatinib, nilotinib, bosutinib, ponatinib, asciminib) vs. Imatinib was evaluated on Major adverse cardiovascular events (ACS, heart failure, stroke, PAD, and revascularization) and overall survival (HR 3.5, p=0.02). Compared with imatinib, nilotinib increased acute coronary syndrome risk and dasatinib increased heart failure risk in CML patients.
Synapse has enriched 10 related papers. Consider them for comparative context: